Back to overview
ISRCTN16756340

Effects of an 8-week birth preparation intervention on women's mental well-being

Data source: WHO (Imported from 01.11.2024)
Changed: Jul 10, 2024, 1:00 AM
Disease category:

Health conditions (Data source: WHO)

Fear of childbirth; mental health in pregnant women
Mental and Behavioural Disorders

Interventions (Data source: WHO)

The intervention group undergoes an eight-week psychological birth preparation program, which is provided via an online application with the name MyDoula. The program contains daily morning mindfulness exercises, evening meditations and two units per week, each including psychoeducation and an exercise part (e.g. reflection exercises run via chatbot). The app use was self-guided.

Participants randomized to the control group receive Treatment as Usual (TAU)/no treatment.

Inclusion/Exclusion Criteria (Data source: WHO)

Gender: Female
Inclusion criteria: Pregnant women between the 20.1 and 27.0 week of pregnancy
Exclusion criteria: 1. Aged 17 years old and younger
2. German is not at a native language level
3. Taking psychotropic drugs, having a psychological diagnosis or being counselled by a psychologist, psychotherapist or psychiatrist at the time of the study
4. Pregnant women that give birth before finalizing the 8 weeks-MyDoula-App-Program (e.g. due to premature birth)
5. When people didn?t agree to be informed about incidental findings, e.g. high scores in the Edinburgh Postnatal Depression Scale (EPDS) screening

Further information on the trial in WHO primary registry

https://www.isrctn.com/ISRCTN16756340

Further information on the trial from WHO database (ICTRP)

https://trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN16756340
Further information on trial

Date trial registered

Mar 8, 2023

Incorporation of the first participant

Sep 8, 2021

Recruitment status

Completed

Academic title (Data source: WHO)

Comparing the MyDoula app intervention with standard care for pregnant women regarding mental wellbeing: Randomized controlled trial

Type of trial (Data source: WHO)

Interventional

Design of the trial (Data source: WHO)

Pre/post longitudinal experimental design with group randomization (Prevention)

Phase (Data source: WHO)

Not Applicable

Primary end point (Data source: WHO)

1. Negative birth expectations measured using the Wijma Delivery Expectations (W-DEQ) questionnaire at baseline and after 8 weeks
2. Support within the relationship measured using the ?Relationship Assessment Scale? questionnaire at baseline
3. Depression Scores are measured using the ?Edinburgh Depression Scale? questionnaire at baseline and 8 weeks later
4. Support within relationships measured using the ?Social support instrument? questionnaire at baseline
5. Mother-Child-Bonding measured using the ?Maternal antenatal attachment scale? questionnaire at baseline and 8 weeks later
6. Mental Wellbeing measured using the ?Mental Wellbeing Scale? questionnaire at baseline and 8 weeks later
7. Mindfulness measured using the ?Frankfurter Fragebogen Achtsamkeit (FFA)? questionnaire at baseline and 8 weeks later
8. Birth mindset measured using the ?Mindset and Birth? questionnaire at baseline

Secundary end point (Data source: WHO)

1. Dyadic coping mechanisms of participants measured using two items of the dyadic coping inventory (DCI) at baseline
2. Quality of current relationship measured using the relationship assessment scale (RAS) at baseline
3. Social support measured using the social support instrument (ESSI) at baseline
4. Prenatal mother-child bonding measured using the Maternal antenatal attachment scale (MAAS) at baseline and 8 weeks after baseline
5. Mental wellbeing measured using the Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS) at baseline and 8 weeks after baseline
6. Mindfulness measured using the Frankfurter Fragebogen Achtsamkeit (FFA) at baseline and 8 weeks after baseline
7. Birthyear, sex, gender, German spoken and understood as native language, graduation, professional qualification, employment, professional position, management position, salary, number of persons in household, persons under 14 in household, marital status, taking psychotropic drugs (exclusion criteria), having psychotherapy (exclusion criteria), having a psychological diagnosis (exclusion criteria), having biological children, type of previous birth(s), type of previous negative birth experiences, abortion, miscarriage, pregnancy week, single/multiple pregnancy, planned pregnancy, worries about high/size of baby, complications during pregnancy, diseases regarding the unborn child, medical risk during pregnancy, worries/fears, main care person, satisfaction with pregnancy care, planned caesarian section (CS) and reasons, trauma, carrying out mindfulness exercises regularly, regular use of other pregnancy apps, using a birth preparation course, use of health apps, using online/offline offers regarding mental health, using online/offline offers regarding mindfulness measured using a Likert scale questionnaire at baseline
8. Pregnancy week, worries about high/size of the unborn baby, complications during pregnancy, diseases regarding the unborn child, medical risk during pregnancy, worries/fears, and planned CS measured using a Likert scale questionnaire at 8 weeks after baseline
9. A possible stressful event during pregnancy measured using a Likert scale questionnaire at 8 weeks after baseline
10. Stress tracking measured daily using a Likert scale questionnaire from baseline until 8 weeks after baseline

Contact information (Data source: WHO)

European Regional Development Fund

Trial results (Data source: WHO)

Results summary

no information available yet

Link to the results in the primary register

no information available yet

Information on the availability of individual participant data

Not expected to be made available
Planned publication in a high-impact peer-reviewed journal

Trial sites

Countries (Data source: WHO)

Austria, Germany, Switzerland

Contact for further information on the trial

Contact for scientific information (Data source: WHO)

Carmen
Birner
Kiepenheuerallee 5
+49 151 12960013
carmen.birner@fh-potsdam.de

Further trial identification numbers

Secondary ID (Data source: WHO)

Nil known
Back to overview